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Vaccination usually works in infectious disease, why not in Cancer? Differences in the
potency of microbial and cancer antigens, poor initiation of an immune response due to
inadequate expression of tumour associated antigens, weak antigens or tolerance induc-
tion and local immune suppression were considered. There is a big difference between a
therapeutic and a prophylactic vaccine.
The opinion of the expert group was that an improved therapeutic efficacy can hardly be
expected by further variation of types of vaccines, schedules, routes of administration and
adjuvants alone. A major hurdle for developing therapeutic cancer vaccines is the need to
effectively monitor the immune response and to be able to use this in an adaptive trial
approach.
End-points of assessment should be different from standard treatments as complete
response or partial responses are usually low, unless combined with other therapies.
Inorder to focus resources toovercome thehurdlesof enhancing the therapeutic efficacyof
cancer vaccines theCancer VaccineClinical TrialWorkingGroup, representing academia and
the pharmaceutical and biotechnology industries has in a consensus process defined ‘A clin-
ical development paradigm for cancer vaccines and related biologics’.
 2007 Elsevier Ltd. All rights reserved.1. Introduction
This session was an in-depth analysis to explore the reasons
why vaccines against cancer have not been developed to the
point where clear clinical benefit has been demonstrated.
Several reasons for this have beendiscussed: Poor initiation
of an immune response due to inadequate expression of tu-
mour-associated antigens, weak antigens or tolerance induc-
tion. Problems specific to vaccinating against cancer antigens
thatwerediscussed includedtheconceptofnon-immunogenic
tumoursandwhether suchexistwhen thevaccine is combineder Ltd. All rights reserved
Ha˚kansson).with the right adjuvant. The fact that weak tumour-associated
antigens could possibly make better vaccines than strong
antigens (whose T-cell repertoire would more likely have been
deleted/tolerated) has to be considered. The concept of toler-
ance and local immune suppression were considered and the
real practical problem of a local secretion of immunosuppres-
sant cytokines, such as IL-10 and TGF-b, and other tumour-
derived substances interfering with even an ineffective
immune response was discussed with the conclusion that the
knowledge about these suppressor mechanisms are still not
sufficient to allow therapeutic measures to overcome them..
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cules, such asDAFCD55 in order to protect tumours from com-
plement-dependent cytotoxicity or apoptosis inhibitors such
as BCL2 to block immune-mediated tumour cell death.1,2
Vaccination usually works in infectious disease, why not in
Cancer? Differences in the potency of microbial and cancer
antigens and cancer-related immunosuppression seems to
be of importance in this context. It is worth noting that where
cancer is clearly associated with infection, the prophylactic
cancer vaccines canbevery effectivewith regards to incidence.
The first of these is liver cancer (hepatoma) caused by HBV, a
vaccine which has been available for over 20 years and which
by preventing infection in the first place will have an 80–90%
predicted reduction in incidence.3 The recent success of two
anti-HPV vaccines from Sanofi Aventis and GSK could have
the same dramatic effect on reducing the incidence of cancer
of the cervix in the next few years.4 In this regard, it is worth
noting that not all infections that cause cancer can be readily
vaccinated against and it is anticipated that a vaccine against
hepatitis C virus, which also causes liver cancer after decades
of chronic infection, will be much more difficult to develop.
2. Vaccines in cancer today
With regards to vaccines against cancer, it is appreciated that
there is a big difference between a therapeutic vaccine with
macroscopic residual disease as opposed to a prophylactic vac-
cine given after total surgical resection to reduce the chances
of disease recurrence. Issues discussed with regards to both
were: the type of vaccine, schedule and adjuvants. The opinion
of the expert group was that various types of vaccines, sched-
ules, routes of administration and adjuvants have been thor-
oughly explored and that a major breakthrough regarding
the therapeutic efficacy of vaccination in cancer can hardly
be expected by further variation of these parameters.
A major hurdle for developing therapeutic cancer vaccines
is the monitoring of the immune response; what is the rele-
vant immune response and how is it best measured? Initia-
tion of an immune response can be measured as the
appearance of antigen-specific T-cells in the circulation or
the appearance of tumour-specific antibodies. The role of
inflammatory cells being recruited to the tumour and possible
cytotoxic activity are well recognised. The need to be able to
monitor immune-mediated tumour regressive changes is
clearly an important end-point for therapeutic vaccines.5
The possible role of imaging methods were discussed. Nano-
particle loaded leukocytes combined with MRI are useful in
the study of distribution and tumour recruitment of these
cells.6 One possibility is to use the effect on circulating tu-
mour cells as a substitute for anti-tumour efficacy, as shown
in a recent breast carcinoma study.7 However, again the utility
of such tests are limited by not measuring some important
aspects of immune-mediated cancer control, e.g. recruitment
of inflammatory cells and their intra-tumoural migration.
A major aspect, which was addressed, was ‘is it really fea-
sible to expect a vaccine monotherapy to be effective in a
therapeutic scenario?’ It is clearly accepted that monoclonal
antibodies, such as Herceptin and Avastin, are more effective
when given with chemotherapy and in a vaccine situation
that GVAX may induce better responses when given withanti-CTLA4.8 Therefore, there could be a compelling reason
to combine biologicals early on, but this raises major regula-
tory hurdles with regards to combinations in early disease.
The possible synergy of combinations of two non-approved
biologicals raises the question of being able to obtain a licence
for the combination, as opposed to having to take them
through to registration individually. Also, there is now consid-
erable literature that combining vaccines with radiotherapy,
some chemotherapy regimens, and endocrine treatment can
lead to better clinical outcome and that combining cytokines,
anti-angiogenics and anti-inflammatory can lead to enhance-
ment in preclinical models.9 It is possible that not all combi-
nations are additive or synergistic, such as TKIs, which may
have a detrimental effect on immunologically active cells.
The session focused on major practical issues as to which
is the best type of disease to target, the best stage and the
most appropriate antigen adjuvant combination. The more
recent data discussed above led to discussions as to exploring
combinations from day one, where pre-clinical data was
strongly supportive.
A particular practical point is, if a vaccine looks to be the
best candidate but requires an adjuvant or cytokine to opti-
mise immunogenicity, how is this best handled if both vac-
cine and adjuvants are in different IP ownership.
The rapid evolvement of these types of biotherapies was
highlighted by an analysis of the increase of registration
applications to the regulatory authorities over the years. Prac-
tical issues of the type of vaccine to be employed in a specific
situation were explored in detail with specific relationship to
the regulatory and other requirements, e.g. the regulatory
requirements for peptide vaccines are considerably different
from cell-based vaccines or genetically modified cell-based
vaccine. Cell-based vaccines, if not genetically modified, are
defined as somatic cell therapies. This entity and the gene
therapy products are classified as advanced therapy medici-
nal products according to Directive 2001/83/EC annex I part
IV. In this regard, the number of gene therapy clinical trial
applications in the EU has increased significantly over the last
3 years from 9 in 2005, to 16 in 2006, to 23 in March 2007, with
the majority of these being for cancer. A similar situation is
seen for somatic cell therapy clinical trial applications, going
from 13 in 2005, to 40 in April 2006 and 71 in March 2007.
Again, the majority of these are in cancer. Of interest is that
in the cell therapy clinical trial applications there is an in-
crease in cancer vaccines in combination with other therapies
in phase IIb and phase III trials compared to phase II studies.
With regards to assessing the effect of cancer vaccines per
se, it was widely felt that the end-points of assessment are
different from standard treatments in that complete response
or partial responses are usually low, unless combined with
other therapies. Static disease and increased quality of life
has been an acceptable end-point for much of the phase II
development. Indeed, a major potential benefit for cancer
vaccines may be to enhance static disease in cases where
there is minimal tumour burden and when disease progres-
sion is seen, for other modalities to be added. A good example
of this is prostate cancer where vaccines have been shown to
be effective on the relevant surrogate markers, such as PSA,
and that even a reduction in rate of the rise of PSA may cor-
relate with an increased time to disease progression. The fact
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cine before standard endocrine treatment strongly argues for
such treatments to be used before endocrine therapy.10
It was also highlighted that in the case of cancer vaccines,
in particular, the ability to identify the predicted immune re-
sponses and to be able to analyse surrogate tumour markers
for response were particularly necessary to rapidly advance
suitable candidates and possible combinations into the
clinic.11
In spite of the vast majority of cancer vaccine development
work being done inmelanoma, it was recognised that the vac-
cine with the most likely chance of immediate registration
was in fact aimed at prostate cancer. This is a dendritic cell-
based candidate from Dendreon, who have analysed trials
to show that there is a significant survival advantage in pa-
tients given the vaccine.12 The session agreed that clinical re-
sults obtained recently with therapeutic cancer vaccines/
immunotherapies looked more promising than in the past
and that a breakthrough in terms of approval for such thera-
pies could be expected in the coming years. In fact, it would
more likely be approved for non-melanoma vaccine indica-
tions, such as prostate, colorectal, lung or renal cancer.13
In order to focus resources to overcome the hurdles of
enhancing the therapeutic efficacy of cancer vaccines the
Cancer Vaccine Clinical Trial Working Group, representing
academia and the pharmaceutical and biotechnology indus-
tries has in a consensus process defined ‘A clinical develop-
ment paradigm for cancer vaccines and related biologics’.
This work was summarised at the present symposium by
Hoos.11 The rationale for this new paradigm is that cancer
vaccines are different from cytotoxic drugs and other types
of molecular targeted therapies and they should be developed
according to more flexible and focused guidelines. Four major
topics were addressed: (1) end-points for clinical trials, (2) trial
designs and statistical methods, (3) technical and develop-
mental challenges, and (4) combination therapy.
The proposed paradigm suggests therapeutic cancer vac-
cines to be developed in two types of clinical studies: proof-
of-principle trials and efficacy trials. Proof-of-principle trials,
which introduce a novel cancer vaccine into humans, should
include a minimum of 20 or more patients in a homogenous,
well-defined population in an adjuvant setting or without rap-
idly progressive disease in a metastatic setting to allow vac-
cines adequate time to induce biological activity and should
incorporate immune and molecular markers. Objectives
should include initiation of a safety database, determination
of dose and schedule, and demonstration of biological activity
as proof-of-principle. Biological activity is defined as any effect
of the vaccine on the target disease or host immune system
using biological markers as study end-points, for example,
clinical, molecular, or immune response. Immune response
is demonstrated if determined in two separate, established
and reproducible assays at two consecutive follow-up time
points after the baseline assessment. If proof-of-principle tri-
als show such immune response, or other biological or clinical
activity, efficacy trials may be initiated. If none of these end-
points is met, the clinical development plan should be re-eval-
uated to decide if further development is warranted.13,14
Efficacy trials formally establish clinical benefits either
directly or through a surrogate and are encouraged to berandomised studies. This is in contrast to single-arm phase
II trials used for cytotoxic agents, which often use tumour
response rate as the primary end-point and historical con-
trols as a comparator. Efficacy trials may use prospectively
planned adaptive designs to expand from randomised phase
II into phase III studies if well-defined trigger-point criteria
are met, but the cost of incorporating such design elements
should be carefully evaluated. Efficacy trials can also be
exploratory randomised phase II trials or conventional
phase III trials. In addition, conventional clinical end-points
can be adjusted to account for biological features of cancer
vaccines. The concept of efficacy trials allows for an early
assessment of vaccine efficacy based on credible prospective
data.
3. Summary
Delayed benefit (response) occurs after disease progression.
Therefore, the paradigm calls for continuing vaccination ther-
apy if (1) progression is not rapid and is clinically insignifi-
cant; (2) no other therapy is immediately required; or (3) no
effective therapy is available. Often vaccinated patients will
show no clinical response other than stable disease but a pro-
gression will show marked clinical responses to other modal-
ities, such as radiotherapy or chemotherapy. Hence, vaccines
which do not induce a CR on PR can greatly increase survival
with classical treatments and may explain the unexpected
Dendreon results.
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